Solitary Fibrous Tumor Treatment Market is expected to reach US$ 59.3 Mn by 2031

Healthcare Providers Increase Availability of Preventive & Curative Services During Coronavirus Pandemic

Healthcare utilization has repeatedly been observed to decrease during the ongoing COVID-19 pandemic. Such trends are affecting the growth of the solitary fibrous tumor treatment market. Many individuals still fear contracting the novel coronavirus infection. Hence, healthcare providers should increase the availability of preventive and curative services, especially for the most vulnerable populations such as older people, children, and for people living with chronic conditions.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111787

Stakeholders in the solitary fibrous tumor treatment market are ensuring continuity of the delivery of essential healthcare services during the pandemic. They are taking efforts to adhere to government guidelines to reorganize and maintain safe access to essential health services. Pharmaceutical companies are maintaining optimum inventory levels to ensure robust supply of life-saving therapeutics.

Lack of Evidence Base for Treatment Affecting Market Growth

The solitary fibrous tumor treatment market is expected to reach US$ 59.3 Mn by 2031. However, it has been found that there is no consensus guideline on the management of solitary fibrous tumors of the pleura (SFTP) and the evidence base for treatment is limited, resulting in large variations in care. Nevertheless, stakeholders are fueling their R&D efforts to increase the availability of treatments for solitary fibrous tumor (SFT).

Pazopanib holds promising potentials for advanced solitary fibrous tumor treatment. This multikinase inhibitor helps to address translocation-associated soft tissue sarcoma. Pazopanib therapy is being associated with radiological evidence of tumor response in many patients.

Multi-disciplinary Approach Holds Promising Potentials in Increasing Patient Outcomes

In order to increase patient outcomes, companies in the solitary fibrous tumor treatment market are increasing their research in a multi-disciplinary approach. They are mainly focusing on the identification of the hallmark NAB2-STAT6 fusion that is emerging as a foundation for future translational work to identify subtype-specific therapy for the subset of SFTs that require systematic treatments.

Surgery remains the gold standard for increasing medical outcomes in the solitary fibrous tumor treatment market. On the other hand, antiangiogenic treatment is found to be effective for unresectable disease. There is a need for translational work to understand the biology driving the differential behavior of SFT and identify more effective treatments for patients with metastatic disease.

Adoption of Adjuvant Radiation Therapy Helps Control Subtotally-resected Pleural SFTs

The solitary fibrous tumor treatment market is projected to expand at a modest CAGR of 4.5% during the forecast period. Gross tumor resection remains the preferred choice for treatment of SFT. However, risk of blood loss, location, and adhesion might not always allow for this. This has led to the adoption of the adjuvant radiation therapy to achieve local control in subtotally-resected pleural SFTs.

The varying doses of external beam radiotherapy are being delivered to patients in order to improve clinical outcomes. Healthcare providers in the solitary fibrous tumor treatment market are gaining awareness that monitoring and surveillance of patients is important for better outcomes. As such, there is a need for further work on dedifferentiated SFT, which remains poorly understood.

Analysts’ Viewpoint

Since healthcare utilization has increased during the COVID-19 pandemic, telehealth services and mobile apps hold promising potentials to encourage individuals to seek treatment at professional healthcare facilities. Since SFT is a rare subtype of STS (Soft-tissue Sarcoma), stakeholders in the solitary fibrous tumor treatment market should adopt a multi-disciplinary approach to deliver optimal outcomes for patients. It has been found that antiangiogenics are active and their sequential use from first line should be considered, except for dedifferentiated SFT for which chemotherapy is an optimum option. Immunohistochemistry is known to be one of the most sensitive and specific means of diagnosing SFT and is practical & economical as well.

Solitary Fibrous Tumor Treatment Market: Overview

Solitary fibrous tumor (SFT) is a very rare malignant condition that exhibits different clinical behaviors ranging from low to high aggressive SFT, with dedifferentiated SFT (DD-SFT) being the fastest-growing subtype

Solitary fibrous tumors can be classified by the site of origin: pleura, mediastinal, or pulmonary. The most common site of origin within the thorax is the pleura.

Solitary Fibrous Tumor Treatment: Market Drivers

Increase in patient awareness about personal health boosts the demand for early diagnosis of rare cancer. Patients are more aware and proactive about their health and are willing to seek physician’s advice at an early stage.

Increase in per capita disposable income is encouraging people to spend more on healthcare, which, in turn, propels the global solitary fibrous tumor treatment market

Awareness initiatives have increased public visibility of new treatments and diagnostic methods, thereby generating interest among solitary fibrous tumor patients

Market Segmentation: Solitary Fibrous Tumor Treatment Market

In terms of treatment, the global solitary fibrous tumor treatment market has been classified into surgery, radiation therapy, and adjuvant chemotherapy

Based on end-user, the global solitary fibrous tumor treatment market has been divided into hospitals, ambulatory surgical centers, and clinics

Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The solitary fibrous tumor treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Solitary Fibrous Tumor Treatment Market

The global solitary fibrous tumor treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The U.S. held significant share of the solitary fibrous tumor treatment market in North America in 2020. The country is expected to retain market share during the forecast period. Robust healthcare infrastructure and early adoption of advanced treatment procedures can be attributed to the U.S.’s dominance of the solitary fibrous tumor treatment market in the region.

Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and India, are projected to drive the solitary fibrous tumor treatment market in the region.

Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the solitary fibrous tumor treatment market report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031

The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the solitary fibrous tumor treatment market and existing companies to increase market share and in the decision-making process

Major Players

The report concludes with the company profiles section that includes key information about the major players in the global solitary fibrous tumor treatment market

Leading players analyzed in the solitary fibrous tumor treatment market report are

• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Bayer AG
• Novartis AG

Each of these players has been profiled in the solitary fibrous tumor treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in Solitary Fibrous Tumor Treatment Market Report

• What is the sales/revenue generated by treatment providers across all regions during the forecast period?
• What are the opportunities in the global solitary fibrous tumor treatment market?
• What are the major drivers, restraints, opportunities, and threats in the global market?
• Which region is set to expand at the fastest CAGR during the forecast period?
• Which application segment is expected to generate the highest revenue globally in 2031?
• What are the market positions of different companies operating in the global market?

Solitary Fibrous Tumor Treatment Market – Segmentation

Treatment

• Surgery
• Radiation Therapy
• Adjuvant Chemotherapy

End-user

• Ambulatory Surgical Centers
• Hospitals
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111787/2900